title: Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.
abstract: Circulating HGV-RNA was determined in 117 patients with HCV-related chronic liver disease and in 200 healthy blood donors. The patients, aged 50.8+/-13.8 years, were classified as chronic hepatitis (CH; n = 82), liver cirrhosis (n = 25) and hepatocellular carcinoma (HCC; n = 10). HGV-RNA was detected in 5 (4.3%) patients, all with CH and in 10 (5%) of blood donors. The majority of all groups (52% to 70%) were infected with HCV genotype II/1b, including 4/5 patients with HGV co-infection. Of 5 patients with HGV co-infection, 4 were positive for anti-HBs and anti-HBc and none exhibited jaundice. A 24-week course of interferon treatment with 12-month follow-up was achieved in 27 patients with chronic active hepatitis, including 3 with HGV co-infection. Of these, 55.6% responded to the therapy, but only 6/27 (22.2%) patients were sustained responders. The majority of sustained responders were HCV genotype III/2a (4/6) while genotype II/1b was found in the majority of patients with relapse (7/9) and non-responders (9/12). At the 48- month follow up, 2/6 sustained responders (one with HGV co-infection) became HCV RNA positive. These results show that the prevalence of HGV infection in HCV-related chronic liver disease is low, as in the general population, and is found in younger patients with chronic hepatitis. HGV coinfection does not interfere with clinical severity, disease progression or response to interferon in patients with HCV-related chronic liver disease. The favorable factors ofinterferon treatment for HCV infection are young age, low HCV-RNA levels and HCV genotype III/2a.
authors.affiliation: Department of Medicine, Ramathibodi Hospital, Mahidol University Bangkok, Thailand.
authors.forename: C
authors.initials: C
authors.lastname: Pramoolsinsap
authors.forename: Y
authors.initials: Y
authors.lastname: Poovorawan
authors.forename: T
authors.initials: T
authors.lastname: Sura
authors.forename: A
authors.initials: A
authors.lastname: Theamboonlers
authors.forename: N
authors.initials: N
authors.lastname: Busagorn
authors.forename: S
authors.initials: S
authors.lastname: Kurathong
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000821:virology*; D005260:Female; D018067:Flaviviridae / Q000235:genetics* / Q000302:isolation & purification; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000150:complications / Q000235:genetics / Q000628:therapy; D006525:Hepatitis, Viral, Human / Q000150:complications / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000821:virology*; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000821:virology*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000032:analysis
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral